ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

Upcoming presentations at the ASCO meeting in Chicago highlight potential practice-changing studies in cancer care.

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

Findings are among nine Decipher-focused abstracts being presented at annual conference “We look forward to the presentation of important new data examining the role of adverse molecular features in ...

PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...

VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and ...

Veracyte specializes in advanced genomic testing for cancer diagnosis and treatment guidance. Its main business is providing diagnostic tests that help clinicians more accurately diagnose and manage ...